Akebia Therapeutics (AKBA) Competitors $3.56 -0.28 (-7.29%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$3.56 +0.00 (+0.03%) As of 07/25/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKBA vs. SRRK, ZLAB, ACLX, PTCT, ACAD, VKTX, SWTX, AAPG, MLTX, and PTGXShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Scholar Rock (SRRK), Zai Lab (ZLAB), Arcellx (ACLX), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Ascentage Pharma Group International (AAPG), MoonLake Immunotherapeutics (MLTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Its Competitors Scholar Rock Zai Lab Arcellx PTC Therapeutics ACADIA Pharmaceuticals Viking Therapeutics SpringWorks Therapeutics Ascentage Pharma Group International MoonLake Immunotherapeutics Protagonist Therapeutics Akebia Therapeutics (NASDAQ:AKBA) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Is AKBA or SRRK more profitable? Scholar Rock has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -24.51%. Akebia Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-24.51% N/A -18.92% Scholar Rock N/A -118.22%-82.01% Does the media prefer AKBA or SRRK? In the previous week, Scholar Rock had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 9 mentions for Scholar Rock and 6 mentions for Akebia Therapeutics. Scholar Rock's average media sentiment score of 1.33 beat Akebia Therapeutics' score of 0.95 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer AKBA or SRRK? Akebia Therapeutics currently has a consensus target price of $6.75, suggesting a potential upside of 89.61%. Scholar Rock has a consensus target price of $42.67, suggesting a potential upside of 9.54%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has more volatility & risk, AKBA or SRRK? Akebia Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Which has stronger valuation & earnings, AKBA or SRRK? Akebia Therapeutics has higher revenue and earnings than Scholar Rock. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$160.18M5.84-$69.41M-$0.21-16.95Scholar Rock$33.19M111.43-$246.29M-$2.53-15.40 Do insiders & institutionals hold more shares of AKBA or SRRK? 33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryAkebia Therapeutics and Scholar Rock tied by winning 8 of the 16 factors compared between the two stocks. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$934.98M$2.51B$5.74B$9.54BDividend YieldN/A1.77%4.71%4.02%P/E Ratio-16.959.5828.4120.06Price / Sales5.84668.34443.6492.77Price / CashN/A164.0436.1858.54Price / Book-15.485.168.655.87Net Income-$69.41M$30.99M$3.25B$258.89M7 Day Performance-7.77%7.73%4.31%3.75%1 Month Performance-2.47%19.78%11.60%12.29%1 Year Performance147.22%-1.37%35.38%17.86% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics3.801 of 5 stars$3.56-7.3%$6.75+89.6%+147.2%$934.98M$160.18M-16.95430High Trading VolumeSRRKScholar Rock3.4298 of 5 stars$41.12+1.0%$42.67+3.8%+319.7%$3.90B$33.19M-16.25140ZLABZai Lab3.127 of 5 stars$34.66+3.2%$54.28+56.6%+97.1%$3.85B$418.33M-13.921,869Positive NewsGap DownACLXArcellx2.2744 of 5 stars$69.39+2.7%$111.23+60.3%+10.7%$3.82B$107.94M-23.2180News CoveragePositive NewsPTCTPTC Therapeutics4.5285 of 5 stars$47.86+0.5%$65.00+35.8%+31.2%$3.79B$806.78M7.351,410News CoveragePositive NewsAnalyst RevisionACADACADIA Pharmaceuticals4.1552 of 5 stars$22.28-1.2%$27.88+25.1%+21.5%$3.73B$957.80M16.26510Positive NewsAnalyst ForecastVKTXViking Therapeutics4.8466 of 5 stars$31.94-0.2%$87.15+172.9%-47.8%$3.59BN/A-27.7720Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSWTXSpringWorks Therapeutics1.2683 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230AAPGAscentage Pharma Group InternationalN/A$39.71-1.7%N/AN/A$3.46B$134.35M0.00600Lockup ExpirationGap DownMLTXMoonLake Immunotherapeutics2.2812 of 5 stars$53.57+0.9%$74.50+39.1%+23.0%$3.43BN/A-23.292News CoveragePositive NewsOptions VolumePTGXProtagonist Therapeutics1.3724 of 5 stars$55.22-0.5%$66.10+19.7%+36.9%$3.42B$434.43M73.63120News CoverageInsider Trade Related Companies and Tools Related Companies SRRK Alternatives ZLAB Alternatives ACLX Alternatives PTCT Alternatives ACAD Alternatives VKTX Alternatives SWTX Alternatives AAPG Alternatives MLTX Alternatives PTGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKBA) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKBA Stock Alerts